Monitor for future share count increases upon conversion of the notes, which could dilute existing shareholders significantly. Given the 10% discount and CMND's $1M market cap, this financing may signal financial stress and could pressure the stock price.
Price Chart
Executive Summary
Clearmind Medicine Inc. (CMND) announced a $2.7 million financing through the issuance of convertible promissory notes to CLA Investors at a 10% discount, with a cash purchase price of $2.43 million. This is part of a previously announced $10 million funding facility. The transaction is expected to close on April 21, 2026.
Key Facts
- Company issued convertible promissory notes with $2.7 million aggregate principal amount
- Investors paid $2.43 million in cash (90% of principal), representing a 10% discount
- Part of a $10 million funding facility first announced on September 17, 2025
- Transaction expected to close on or about April 21, 2026
- Notes will be convertible, indicating potential future equity dilution
Financial Impact
Immediate cash inflow of $2.43 million at a 10% discount; potential significant future dilution upon conversion of notes
Risk Factors
- Substantial equity dilution when convertible notes are converted
- Downward pressure on share price due to discounted financing and potential overhang
- Risk of further dilutive financings if company requires additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-045702 |
| Document: 0001213900-26-045702-index-headers.html | 0001213900-26-045702 |
| Document: 0001213900-26-045702-index.html | 0001213900-26-045702 |
| Document: 0001213900-26-045702.txt | 0001213900-26-045702 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $6.12 (+3.40%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $6.12 (−5.83%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers